Digbi Health Expands Its Multi-Condition Care Platform to Enhance Tolerability and Efficacy of GLP-1 Drugs

PALO ALTO, Calif., January 17, 2025 /Digbi Newswire/ -- Digbi Health, the leader in Precision Biology care, is advancing obesity management with enhancements to GLP Compass™, its GLP-1 telehealth program. Digbi Health has introduced an advanced obesity test that includes genetic, blood glucose and gut microbiome biomarkers, together with a clinical GI health assessment, to personalize nutritional and pharmacotherapy support so that each member receives care matched to their biology and lifestyle.

Understanding the different causes of obesity

The causes of obesity, and the efficacy and tolerability of GLP-1 medication, vary widely among individuals based on genetics, gut microbiome and glucose metabolism. For some, obesity is primarily driven by insulin-related metabolic issues. For others it stems from dysfunction of the gut-brain axis, which influences cravings and hunger regulation as well as GLP-1 side effects such as nausea and diarrhea.

By isolating these profiles, Digbi Health can tailor treatment more precisely, leading to 3X better weight loss outcomes and 5X better drug tolerability than one-size-fits-all GLP-1 companion programs that do not account for a patient's biology, ethnicity and gender.

The first precision biology-based obesity test

Following the launch of GLP Compass™, Digbi Health expanded its obesity test capabilities in 2025. GLP Compass™ gives members clarity on their weight loss path by determining who needs GLP-1 drugs and who can achieve sustainable weight loss through food-as-medicine — helping patients avoid unnecessary medication while reducing cost for employers and health plans.

2025 expansions:

• GLP-1 drug responsiveness prediction — Research indicates that 25% of individuals on GLP-1 drugs lose less than 5% of body weight, while 25% lose more than 15%. By analyzing glucose metabolism, genetic predispositions and the individual gut microbiome, the test predicts drug responsiveness and optimizes treatment modalities.
• GI adverse effect risk assessment — 40% of patients on GLP-1 drugs discontinue the medication, with gastrointestinal adverse effects the primary cause. The test enables the Digbi care team to anticipate and manage those effects, helping members proactively manage nausea and abdominal flare-ups and improve adherence.
• GLP-1 tapering success predictor — This first-of-its-kind tool identifies members who are candidates for tapering or dose reduction based on more than 150 parameters across lifestyle, genetics and gut health, so that members who taper maintain their weight long term.

Digbi developed GLP Compass using AI and millions of data points drawn from the biology, food, medical and lifestyle data of 10,000 patients over a 52-week period.

Our goal is to provide personalized and AI-based nutrition-first care for the top food-related illnesses — obesity, type 2 diabetes, gastrointestinal disorders and mental health. By expanding our industry-leading obesity test, we reinforce our commitment to innovation and safety-first AI-based care.

— Ranjan Sinha, Founder and CEO, Digbi Health

Originally distributed via GLOBE NEWSWIRE.